The reactome pathway knowledgebase.

Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. · 2020

Read The reactome pathway knowledgebase. by Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7145712.txt.

Introduction

Jassal and co-authors describe the Reactome pathway knowledgebase, in Nucleic Acids Research. Reactome maps cell processes, from signal relay and transport to DNA replication and metabolism, as an ordered network of molecular changes in one consistent data model. It serves both as an archive of biological processes and as an analysis tool.

New work extends annotation of human diseases and adds a drug classification, first applied to cardiovascular medicines. Outside experts propose and review new content areas, and contributor pages now link their work to ORCID records. A new layout tool draws individual reaction diagrams automatically, and a redesigned hierarchy display helps users read pathway analysis results. Researchers use Reactome to interpret gene expression and tumor mutation data.

Catalog record

CREATORJassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F, May B, Milacic M, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE19 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7145712

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The reactome pathway knowledgebase By Bijay Jassal, Lisa Matthews, Guilherme Viteri, Chuqiao Gong, Pascual Lorente, Antonio Fabregat, Konstantinos Sidiropoulos, Justin Cook, Marc Gillespie, Robin Haw, Fred Loney, Bruce May Published in: Nucleic Acids Research DOI: 10.1093/nar/gkz1031 ABSTRACT Abstract The Reactome Knowledgebase (https://reactome.org) provides molecular details of signal transduction, transport, DNA replication, metabolism and other cellular processes as an ordered network of molecular transformations in a single consistent data model, an extended version of a classic metabolic map. Reactome functions both as an archive of biological processes and as a tool for discovering functional relationships in data such as gene expression profiles or somatic mutation catalogs from tumor cells. To extend our ability to annotate human disease processes, we have implemented a new drug class and have used it initially to annotate drugs relevant to cardiovascular disease. Our annotation model depends on external domain experts to identify new areas for annotation and to review new content. New web pages facilitate recruitment of community experts and allow those who have contributed to Reactome to identify their contributions and link them to their ORCID records. To improve visualization of our content, we have implemented a new tool to automatically lay out the components of individual reactions with multiple options for downloading the reaction diagrams and associated data, and a new display of our event hierarchy that will facilitate visual interpretation of pathway analysis results. INTRODUCTION At the cellular level, life is a network of molecular reactions that enable signal transduction, transport, DNA replication, protein synthesis and intermediary metabolism. A variety of online resources capture aspects of this information at the level of individual reactions such as Rhea (1) or at the level of reaction sequences spanning various domains of biology such as KEGG (2), MetaCyc (3) or PANTHER (4). The Reactome Knowledgebase is distinctive in focusing its manual annotation effort on a single species, Homo sapiens, and applying a single consistent data model across all domains of biology. Processes are systematically described in molecular detail to generate an ordered network of molecular transformations, resulting in an extended version of a classic metabolic map (5,6). The Reactome Knowledgebase systematically links human proteins to their molecular functions, providing a resource that functions both as an archive of biological processes and as a tool for discovering novel functional relationships in data such as gene expression studies or catalogs of somatic mutations in tumor cells. Reactome (version 70—September 2019) has entries for 10 867 human protein-coding genes, 53% of the 20 454 predicted human protein-coding genes (Ensembl release 97—July 2019—http://www.ensembl.org/Homo_sapiens/Info/Annotation), supporting the annotation of 25 849 specific forms of proteins distinguished by co- and post-translational modifications and subcellular localizations. These function with 1856 naturally occurring small molecules as substrates, catalysts and regulators in 11 638 reactions annotated on the basis of data from 30 398 literature references. These reactions are grouped into 1803 pathways (e.g. interleukin-15 signaling, phosphatidylinositol phosphate metabolism and receptor-mediated mitophagy) grouped into 26 superpathways (e.g. immune system, metabolism and autophagy) that describe normal cellular functions. Notable recent additions include extended annotations of SUMOylation and NEDDylation reactions and their regulatory consequences, annotations of NOTCH and RUNX signaling processes, systematic annotation of the processes of autophagy, and annotation of the metabolism of arachidonate-derived proresolvin mediators. An additional ‘disease’ superpathway groups 484 annotations of disease counterparts of these normal cellular processes. These disease annotations include 1599 variant proteins and their post-translationally modified forms derived from 308 gene products, used to annotate 970 disease-specific reactions, tagged with 387 Disease Ontology terms (7). Notable recent changes in Reactome include expanding the scope of the project to support annotation of the molecular function of drugs, developing new tools to facilitate community participation in annotation and to explicitly acknowledge it, and developing new web features to improve the layout of individual reactions and the visualization of our event hierarchy. ANNOTATING MOLECULAR MECHANISMS OF DRUG ACTION A ‘drug’ is not a molecularly distinct kind of physical entity but rather a role that the entity can assume under specific circumstances. For Reactome, a drug is a physical entity not normally present in a human system and not a normal dietary constituent that when introduced into the system interacts with the naturally occurring components of the system to modulate their molecular functions. A new ‘drug’ class of physical entities in our data model distinguishes chemical drugs (e.g. β-blockers) from protein drugs (e.g. therapeutic antibodies) and RNA drugs (e.g. synthetic small RNAs). As shown for the antithrombotic chemical apixaban in Figure 1A, each chemical drug instance is mapped to its counterpart in IUPHAR (8) and if one is available in ChEBI (9) and for additional pharmacological data. The drug instance is also associated with a disease target using terms from the Disease Ontology (7) and a subcellular location using terms from the GO cellular component ontology (10). When several such drugs form a chemically related family with a single target and mechanism of action, we group them into a set (Figure 1B); that set is then used to create reactions to annotate the shared action (either negative or positive) of the set members on the target. In the case of apixaban and closely related chemical drugs that bind and inhibit Factor Xa both alone and as a complex with Factor Va, a reaction shows drug binding to the complex to form a drug:protein complex that negatively regulates cleavage of Factor II (Figure 1C). [Figure: Annotating drugs: antithrombotic activity of Factor Xa inhibitors. (A) The Reactome annotation of apixaban associates it with reference information in the ChEBI (1) and IUPHAR (2) databases, with a disease process, pulmonary embolism, from the Disease Ontology (3), with a cellular component, ‘extracellular region’ from GO (4), and with literature references from PubMed (5). Each of these entries is associated with a Reactome identifier; following the link on the Reactome page takes the user to the web page for that entry in the reference database. (B) Apixiban is grouped with four other similarly annotated small molecules (1), betrixaban, endoxaban, reviroxaban and eribaxan, to form the set of Factor Xa inhibitors. (C) The shared molecular function of this set of molecules (1) is represented by annotating their binding (2) to the complex of Factors Va and Xa (3) to form an inactive complex (4), thereby negatively regulating (5) the cleavage (6) of Factor 2 (7). In our iconography, entities with a drug role are shown with their usual icon shapes but shaded purple and with an ‘Rx’ tag in the lower right corner of the icon.] Our September 2019 release includes annotations of effects of 222 drugs, mostly chemical drugs in widespread use to treat thrombosis and other cardiovascular diseases. Work is underway to extend annotations to drugs involved in other disease processes, and to other stages of the complete drug life cycle, linking the molecular function of its active form to reactions for its uptake, its activation if it enters the body in prodrug from, and its inactivation and elimination. Of all the exogenous molecules that can perturb human biological processes, which ones qualify as drugs? A molecule in widespread clinical use as indicated by its IUPHAR annotations is clearly qualified. In addition, we include molecules whose potential therapeutic mechanisms of

Read the complete text